Clopidogrel

Use

Clopidogrel was launched in the US as a potent inhibitor of platelet aggregation for the preventive management of secondary ischemic events, including MI, stroke and vascular deaths. Clopidogrel can be synthesized in 4 steps (including an optical resolution to the S active enantiomer) from 2-(2- ch1orophenyl)-glycine, the key step being the cyclization to thienopyridine with formaldehyde and acetic acid. Clopidogrel belongs to the original chemical class of Ticlopidine, but shows fewer side effects (in particular, bone-marrowsuppressing effects) at the dosage generally used. Like Ticlopidine, it is an Adenosine diphosphate (ADP) antagonist acting at the purinergic P2y receptor. In in vivo experiments with rabbits, Clopidogrel shows a maximal antiaggregant effect at 20mg/kg po, reducing adhesion of platelets to the vascular subendothelium ; moreover, it reduces myointimal thickening occuring after endothelial injury of rat carotid artery. Clopigrel does not affect platelet aggregation in vitro ; actually, its in vivo activity is highly dependent on hepatic metabolism. The results of a CAPRIE trial (Clopidogrel versus Aspirin in patients at risk of ischemic events) demonstrated that Clopidogrel was well tolerated and more effective than aspirin.

Clopidogrel manufacturers

• Clopidogrel
• 
• US $0.00-0.00 / Kg
• 2024-04-09
• CAS:113665-84-2
• Min. Order: 1Kg
• Purity: 99.9%
• Supply Ability: 200tons

• Clopidogrel
• 
• US $100.00 / kg
• 2023-08-15
• CAS:113665-84-2
• Min. Order: 1kg
• Purity: 99%
• Supply Ability: 1000tons

• Clopidogrel
• 
• US $200.00 / kg
• 2023-06-26
• CAS:113665-84-2
• Min. Order: 1kg
• Purity: 99%
• Supply Ability: 1000kg/Month